# A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

> **NCT05796570** · PHASE2 · RECRUITING · sponsor: **Franziska Wachter** · enrollment: 37 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Myeloid Malignancies
- MDS
- Inherited Bone Marrow Failure Syndrome
- Myeloid Neoplasm
- Aml

## Interventions

- **DRUG:** Decitabine
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT05796570
- **Lead sponsor:** Franziska Wachter
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-19
- **Primary completion:** 2026-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- Harvard Clinical and Translational Science Center (Harvard Catalyst)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05796570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05796570, "A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05796570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*